Blood Culture Tests Market
Blood Culture Tests Market by Product (Consumables, Instruments), Method (Manual, Automated), Technology (Culture-Based, Molecular, Proteomics), Application (Bacteremia, Fungemia), End User (Hospital, Academic Research), Region - Global Forecast to 2031
BLOOD CULTURE TESTS MARKET SIZE, SHARE & GROWTH SNAPSHOT
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global blood culture tests market is projected to grow from USD 6.66 billion in 2026 to USD 8.94 billion by 2031, at a CAGR of 6.1% during the forecast period. The market was valued at USD 6.20 billion in 2025. The market is driven by the rising burden of bloodstream infections (BSIs) and sepsis, increasing incidence of healthcare-associated infections (HAIs), growing concerns regarding antimicrobial resistance (AMR), and increasing hospital and critical care admissions. The growing emphasis on early and accurate identification of bloodstream pathogens and antimicrobial stewardship is supporting blood culture testing volumes across hospital and clinical laboratories.
KEY TAKEAWAYS
-
MARKET SNAPSHOT:
Base Year Market Size (2025): USD 6.20 Billion
Current Market Size (2026): USD 6.66 Billion
Forecast Market Size (2031): USD 8.94 Billion
CAGR (2026–2031): 6.1% -
SEGMENT LEADERSHIP:
Regional Outlook: Asia Pacific is expected to register the fastest growth rate in the blood culture tests market during the forecast period, driven by expanding hospital and diagnostic laboratory infrastructure, improving access to microbiological testing, and increasing adoption of automated blood culture systems.
Product Leader: Consumables segment accounted for the largest market share of 73.8% in 2025.
Method Leader: Conventional/manual blood culture segment held the largest market share of 56.8% in 2025.
Technology Leader: Culture-based segment captured the largest market share of 72.8% in 2025.
Application Leader: Bacteremia segment accounted for the largest market share in 2025.
End User Leader: Hospital laboratories segment held the largest market share in 2025. -
MARKET OUTLOOK & COMPETITIVE LANDSCAPE:
Waters Corporation (US), bioMérieux (France), Thermo Fisher Scientific, Inc. (US), and DiaSorin S.p.A. (Italy) were identified as star players, which correspondingly are supported by their strong market presence and extensive product portfolios.
Scenker Biological Technology Co., Ltd. (China), HiMedia Laboratories Pvt. Ltd. (India), Labotronics Scientific (US), and Biobase Group (China) have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas.
The blood culture tests market is experiencing steady growth due to the rising burden of bloodstream infections (BSIs) and sepsis, increasing incidence of healthcare-associated infections (HAIs), and growing concerns regarding antimicrobial resistance (AMR). Increasing hospital and critical care admissions, expanding use of blood cultures for early pathogen detection, and greater emphasis on antimicrobial stewardship are driving demand for blood culture testing. Additionally, technological advancements in automated blood culture systems, culture media, rapid microbial identification, and integrated laboratory workflows, coupled with expanding diagnostic infrastructure and increasing healthcare expenditure, are improving laboratory efficiency and supporting market growth globally.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The influence of clinical and technological trends on the blood culture tests market is driven by the growing emphasis on early diagnosis of bloodstream infections (BSIs) and sepsis, increasing burden of healthcare-associated infections (HAIs), and rising concerns regarding antimicrobial resistance (AMR). Key applications of blood culture testing include the detection of bacteremia, fungaemia, and mycobacterial bloodstream infections, particularly among critically ill, immunocompromised, neonatal, and hospitalized patients. Major trends shaping the market include the increasing adoption of automated blood culture systems, laboratory automation, rapid molecular diagnostics, mass spectrometry-based microbial identification, and faster antimicrobial susceptibility testing (AST) to reduce turnaround times and support timely treatment decisions.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Increasing number of sepsis patients and cost of treatment
-
High incidence of nosocomial bloodstream infections
Level
-
High cost of automated blood culture instruments
-
Lack of trained laboratory technicians
Level
-
Growth opportunities in emerging economies
-
Increased need to identify antibiotic-resistant microorganisms
Level
-
Long turnaround time associated with conventional blood culture workflows
-
Blood culture contamination and pre-analytical errors
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Increasing number of sepsis patients and cost of treatment
The increasing burden of sepsis and bloodstream infections (BSIs) is significantly driving demand for blood culture tests worldwide. Sepsis requires rapid diagnosis and timely initiation of appropriate antimicrobial therapy, making blood culture testing a key component of the diagnostic workflow for identifying causative bacterial and fungal pathogens. In addition, the high cost of sepsis management, particularly among patients requiring intensive care, prolonged hospitalization, and treatment for complications, is increasing the emphasis on early pathogen identification and targeted antimicrobial therapy.
Restraint: High cost of automated blood culture instruments cost of intravascular blood culture tests
The high acquisition and implementation cost of automated blood culture systems can limit their adoption, particularly among small laboratories and healthcare facilities in low- and middle-income countries. In addition to the initial capital investment, laboratories may incur recurring expenses associated with proprietary blood culture bottles and consumables, instrument maintenance, service contracts, quality control, and laboratory infrastructure. These financial requirements can encourage smaller or resource-constrained laboratories to continue using conventional/manual blood culture methods or centralized testing services.
Opportunity: Growth opportunities in emerging economies
Emerging economies offer significant growth opportunities for the blood culture tests market due to their large patient populations, substantial infectious disease burden, improving healthcare access, and ongoing expansion of hospital and diagnostic laboratory infrastructure. Countries across Asia Pacific, Latin America, the Middle East, and Africa are investing in healthcare capacity, microbiology laboratories, infection surveillance, and diagnostic capabilities. Increasing awareness of sepsis, healthcare-associated infections, and antimicrobial resistance is also strengthening the need for reliable microbiological diagnosis.
Challenge: Long turnaround time associated with conventional blood culture workflows
The long turnaround time associated with conventional blood culture workflows remains an important challenge, particularly when rapid clinical decisions are required for patients with suspected sepsis or severe bloodstream infections. Culture-based diagnosis requires sufficient microbial growth before a blood culture becomes positive, followed by additional steps for pathogen identification and antimicrobial susceptibility testing (AST), which can extend the time required to obtain actionable results. During this period, clinicians may initiate broad-spectrum empirical antimicrobial therapy, potentially contributing to unnecessary antimicrobial exposure and stewardship challenges.
BLOOD CULTURE TESTS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Provides BD BACTEC automated blood culture systems and culture media/bottles for detecting bacterial and fungal bloodstream infections across hospital and clinical microbiology laboratories | Enables continuous automated monitoring | Supports earlier detection of microbial growth | Improves laboratory workflow efficiency | Supports pathogen identification and subsequent AST workflows |
 |
Provides BACT/ALERT blood culture systems and culture bottles for automated detection of bloodstream infections, complemented by microbial identification and antimicrobial susceptibility testing solutions | Enables automated detection of bloodstream pathogens | Supports integrated microbiology workflows | Facilitates faster organism identification and susceptibility testing | Supports antimicrobial stewardship |
 |
Provides Oxoid blood culture and microbiology solutions, including culture media and related products used for cultivation, isolation, and subsequent characterization of microorganisms associated with bloodstream infections | Supports recovery and isolation of bloodstream pathogens | Provides broad microbiology workflow support | Enables downstream microbial identification and susceptibility testing | Supports routine clinical laboratory testing |
 |
Provides molecular diagnostic solutions through Luminex technology, including multiplex assays that can support rapid identification of pathogens and resistance markers associated with bloodstream infections, including testing from positive blood cultures where applicable | Accelerates pathogen identification | Enables multiplex detection of clinically relevant targets | Supports earlier treatment optimization | Complements conventional culture-based workflows |
 |
Through Beckman Coulter Diagnostics, provides microbiology solutions supporting microbial identification and antimicrobial susceptibility testing, complementing blood culture workflows after microbial growth is detected | Supports identification of bloodstream isolates | Enables antimicrobial susceptibility assessment | Improves laboratory workflow efficiency | Supports targeted antimicrobial treatment decisions |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The blood culture tests ecosystem comprises manufacturers, distributors, healthcare providers, clinical laboratories, and other end users, each playing a critical role in enabling the diagnosis and management of bloodstream infections. Manufacturers develop and commercialize automated blood culture instruments, conventional blood culture solutions, blood culture bottles and media, reagents, software, and associated microbiology technologies for the detection of bacterial and fungal pathogens in blood. Distributors facilitate product availability and market penetration through extensive regional and global distribution networks while providing access to instruments and recurring consumables across healthcare facilities. End users, including hospital laboratories, reference laboratories, academic and research laboratories, and other end users, utilize these solutions for the detection of bacteremia, fungaemia, and other bloodstream infections.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Blood Culture Tests Market, by Product
From 2026 to 2031, the consumables segment is expected to record the highest CAGR in the blood culture tests market. This is primarily driven by the recurring utilization of blood culture bottles, culture media, reagents, and related consumables for every blood culture procedure, increasing testing volumes for bloodstream infections and sepsis, and the expanding installed base of automated blood culture systems.
Blood Culture Tests Market, by Method
In 2025, conventional/manual blood culture held the largest share of the blood culture tests market by method and is expected to maintain a significant market position through 2026. Its dominance is primarily attributed to its established clinical use, relatively low capital requirements, broad accessibility, and continued utilization in laboratories with limited access to automated microbiology infrastructure, particularly across developing and resource-constrained markets. However, automated blood culture is gaining adoption due to continuous monitoring, reduced hands-on requirements, improved workflow efficiency, and faster detection of microbial growth.
Blood Culture Tests Market, by Technology
In 2025, culture-based technologies held the largest share of the blood culture tests market and are expected to maintain their dominance through 2026. This is primarily driven by the established role of culture-based methods in detecting viable microorganisms from blood specimens and recovering isolates for subsequent pathogen identification and antimicrobial susceptibility testing (AST).
Blood Culture Tests Market, by Application
In 2025, bacteremia held the largest share of the blood culture tests market by application and is expected to maintain its dominance through 2026. This is primarily attributed to the substantial burden of bacterial bloodstream infections, frequent use of blood cultures in patients with suspected sepsis, and the clinical need to identify causative bacterial pathogens and determine their antimicrobial susceptibility.
Blood Culture Tests Market, by End User
In 2025, hospital laboratories held the largest share of the blood culture tests market by end user and are expected to maintain their dominance through 2026. This is primarily driven by the high volume of blood cultures generated from patients with suspected sepsis and bloodstream infections across emergency departments, intensive care units, oncology units, transplant units, and other inpatient settings.
REGION
Asia Pacific to be fastest-growing region in global blood culture tests market during forecast period
Asia Pacific is expected to register the highest CAGR in the blood culture tests market from 2026 to 2031, driven by expanding healthcare and diagnostic laboratory infrastructure, increasing hospital admissions, and growing investments in clinical microbiology and infectious disease diagnostics. Countries such as China, India, Japan, and South Korea are witnessing continued investments in hospital modernization, laboratory automation, and advanced diagnostic technologies. Additionally, the substantial burden of bloodstream infections, sepsis, and healthcare-associated infections, rising concerns regarding antimicrobial resistance (AMR), and increasing emphasis on antimicrobial stewardship and early pathogen identification are driving blood culture testing volumes across the region.
BLOOD CULTURE TESTS MARKET: COMPANY EVALUATION MATRIX
In the blood culture tests market, bioMérieux (France) is recognized as a dominant player (Star), supported by its strong BACT/ALERT blood culture portfolio, extensive global presence, large installed base, and established expertise in clinical microbiology and infectious disease diagnostics. The company further benefits from complementary pathogen identification and antimicrobial susceptibility testing solutions. In contrast, Bruker Corporation (US) is emerging as a key market participant, primarily through its MALDI-TOF mass spectrometry platforms and related solutions that enable rapid microbial identification following positive blood cultures. Bruker continues to strengthen its position through technological innovation, workflow integration, and expanding adoption across clinical microbiology laboratories.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Waters Corporation (US)
- bioMérieux (France)
- Thermo Fisher Scientific, Inc. (US)
- DiaSorin S.p.A. (Italy)
- Danaher Corporation (US)
- Bruker Corporation (US)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China)
- Accelerate Diagnostics, Inc (US)
- Autobio Diagnostics Co., Ltd (China)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 (Value) | USD 6.20 Billion |
| Market Size in 2026 (Value) | USD 6.66 Billion |
| Market Forecast in 2031 (Value) | USD 8.94 Billion |
| Growth Rate | CAGR of 6.1 % from 2026–2031 |
| Years Considered | 2024–2031 |
| Base Year | 2025 |
| Forecast Period | 2026–2031 |
| Units Considered | Value (USD Million/Billion) |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
WHAT IS IN IT FOR YOU: BLOOD CULTURE TESTS MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Country-wise analysis of the blood culture tests market across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa | Delivered detailed country-level market sizing, growth forecasts, and demand analysis across major regions, with assessment of blood culture testing volumes, automated blood culture adoption, laboratory infrastructure, and demand for instruments and consumables. | Incorporated country-specific analysis of bloodstream infection burden, sepsis incidence, healthcare expenditure, hospital and laboratory infrastructure, diagnostic testing capabilities, and regulatory environment to identify high-growth markets and investment opportunities. |
| Market share analysis and competitive benchmarking of key blood culture tests companies | Provided detailed competitive benchmarking and market share analysis of leading BCT players based on product portfolio, installed base, geographic presence, technology capabilities, distribution reach, and strategic initiatives across culture-based, molecular, and proteomic technologies. | Expanded the competitive landscape by profiling regional and emerging players and assessing recent product launches, regulatory approvals, partnerships, acquisitions, geographic expansions, and technology innovations to evaluate future competitive positioning. |
| Pricing analysis of blood culture tests consumables and instruments | Delivered country-wise pricing analysis of blood culture instruments and consumables, including automated blood culture systems, blood culture bottles/media, and associated consumables, with pricing variations assessed by product type, supplier, and end user. | Incorporated country-level reimbursement frameworks, procurement and tender practices, distributor dynamics, instrument placement models, consumable utilization, and laboratory purchasing patterns to provide a comprehensive assessment of pricing trends and market accessibility across regions. |
RECENT DEVELOPMENTS
- June 2026 : Waters Corporation (US) announced FDA 510(k) clearance for the BD BACTEC FXI Culture System, a next-generation automated blood culture platform designed for high-throughput microbiology laboratories.
- November 2025 : Zynnon (Switzerland) launched Bactify, a next-generation diagnostic platform designed for rapid detection and identification of microbial pathogens directly from positive blood cultures. The platform aims to deliver actionable pathogen identification within hours rather than days, supporting faster clinical decision-making.
- March 2025 : Accelerate Diagnostics, Inc. (US) submitted its Accelerate WAVE System and positive blood culture Gram-negative test kit to the US FDA for 510(k) clearance. The platform is designed to provide rapid identification and antimicrobial susceptibility testing from positive blood cultures, supporting faster selection of appropriate antimicrobial therapy and strengthening the company's presence in rapid bloodstream infection diagnostics.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
Methodology
The objective of this study is to analyze key market dynamics, including drivers, opportunities, restraints, and challenges, as well as the strategies of major players. It aims to monitor developments across leading players, including acquisitions, product launches, expansions, agreements, and partnerships. Additionally, the study will examine the competitive landscape of the blood culture tests market by evaluating market participants based on various criteria within the overarching categories of business and product strategy. To estimate the market size, both top-down and bottom-up approaches were employed. The market breakdown and data triangulation methods were used to assess segment and subsegment sizes.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases, and investor presentations of companies; white papers; certified publications; articles by recognized authors; gold- and silver-standard websites; regulatory bodies; and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
In the primary research process, various sources from the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were industry experts from core and related industries, as well as preferred suppliers, manufacturers, distributors, technology developers, researchers, and organizations across all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information as well as assess prospects.
Note: C-level executives include Chief Executive Officers (CEOs), Chief Financial Officers (CFOs), Chief Operating Officers (COOs), and Vice Presidents (VPs).
Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
Companies are classified into tiers based on their total revenue as of 2025. The tiers are as follows: Tier 1 = >USD 10 billion, Tier 2 = USD 1 billion to USD 10 billion, and Tier 3 = <USD 1 billion.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
For the global market value, annual revenue figures were calculated using revenue mapping for major product manufacturers and OEMs active in the global blood culture tests market. All major product manufacturers were identified at the global and/or country-/regional level. Revenue mapping for the respective business segments/subsegments was done for the major players. Additionally, the global market was split into various segments and subsegments:
- List of major players in the product market by region or country
- Product mapping of various blood culture product manufacturers at the regional and/or country level
- Mapping of annual revenue generated by listed major players from blood culture test products (or the nearest reported business unit/product category)
- Extrapolation of the revenue mapping of the listed major players to derive the global market size of the respective business segments, in terms of value
- Summation of revenue of all companies to arrive at the global blood culture tests market size
The data mentioned above was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.
Data Triangulation
After determining the overall size of the global blood culture tests market using the methodology described above, the market was segmented into several segments and subsegments. The data triangulation and market breakdown procedures were employed, as applicable, to complete the overall market engineering process and obtain exact market value data for the key segments and subsegments. The extrapolated market-related data was triangulated by studying various macro indicators and regional trends from demand- and supply-side participants.
Market Definition
Blood culture testing detects the presence of microbes such as bacteria, yeast, and other microorganisms in a blood specimen. This type of testing determines the nature and severity of blood infections, identifies the causative organisms of blood infections, and helps prevent adverse consequences.
Key Stakeholders
- Molecular diagnostics companies
- Clinical microbiology instrument and consumable manufacturers
- Research and consulting firms
- Clinical diagnostic laboratories
- Healthcare institutions (hospitals, medical schools, group practices, individual surgeons, and
- governing bodies)
- Medical device vendors/service providers
- Research institutes
- Venture capitalists and investors
Report Objectives
- To describe, segment, and forecast the blood culture tests market, by product, method, technology, application, and end user, in terms of value
- To forecast the size of the blood culture tests market in five main regions (along with their respective key countries): North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa, in terms of value
- To provide detailed information about the factors (drivers, restraints, opportunities, and challenges) influencing market growth
- To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall blood culture tests market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To profile the key players in the blood culture tests market and comprehensively analyze their core competencies and market shares
- To analyze competitive developments such as acquisitions, product launches, expansions, collaborations, agreements, partnerships, and R&D activities of the leading players in the market
- To benchmark players within the blood culture tests market using the Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offerings
Available customizations:
Based on the given market data, MarketsandMarkets offers customizations tailored to your company’s specific needs. The following customization options are available for the report:
GEOGRAPHIC ANALYSIS
- Further breakdown of the Rest of European blood culture tests market into Russia, Switzerland, Denmark, Austria, and others
- Further breakdown of the Rest of Asia Pacific blood culture tests market into Hong Kong, Taiwan, and others
- Further breakdown of the Rest of Latin American blood culture tests market into Argentina, Colombia, Chile, Ecuador, and others
- Further breakdown of the Southeast Asian blood culture tests market into Malaysia, Singapore, Australia, New Zealand, and others
COMPETITIVE LANDSCAPE ASSESSMENT
- Market Share Analysis, by region (North America and Europe), which provides the details about the share of the top 3 to 5 key players in the blood culture tests market
- Competitive leadership mapping for established players in the US
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Blood Culture Tests Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free CustomisationTESTIMONIALS
JAYANT RAJPUROHIT
Director of Market Insights, Data and Analytics
SFI Health,
Leading Pharmaceutical Companywww.sfihealth.com/
We at SFI Health approached MarketsandMarkets for an Opportunity Assessment on "Incidence and Prevalence of Focus Indications" as we wanted to know the most attractive HCPs like Physician, Functional MD, Naturopath and Pharmacist. The project was critical for us to ensure our focus on the right target which would enable sustainable growth and profitability for SFI Health. The business insights provided exceeded our expectations and we were extremely impressed. The team at MarketsandMarkets is highly professional and detail oriented and very well understood our business needs. MarketsandMarkets offers a unique combination of expertise and dedicated engagement model. We identified 2 new products to be launched in coming months, based on the research findings provided by MarketsandMarkets. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
BEATRIZ DE LA CALLE
Head of Commercial Analytics
Qualicaps,
Leading Pharmaceutical Companywww.qualicaps.com/
We partnered with MarketsandMarkets for an assessment study on hard empty capsules. The team was extremely professional in understanding our business requirements and we received timely responses to all our queries. The market intelligence and the recommendations has met our business requirements. We were extremely impressed to see the final study results; it really exceeded our expectations. The market intelligence offered by MarketsandMarkets, and clarity on next steps will help us achieve our business objective for the Year 2021. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
Bob Williams,
Senior Director Business Development & Innovation
Bracco Diagnostics Inc.,
Italian Multinational in life sciences sector and a World Leader in imaging diagnosticsimaging.bracco.com/us-en
We were pleased with targeted insights that MarketsandMarkets identified from a custom study on the 'Radiation Dose Management Solutions Market'. Your team identified and characterized the market participants as well as underlying trends accurately. This study was useful to Bracco in formulating business strategies for our dose monitoring product lines and we thank MarketsandMarkets for the job well done.
Cody Coonradt,
Market Development and Strategy Manager
3M Health Information Systems,
Leader in Health care Coding, Payment & Analytics Solutions.www.3m.com/3M/en_US/health-information-systems-us
The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarketsandMarkets, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer.
Their customer first approach and high value engagement model, have given us great analysis and excellent value for money
Growth opportunities and latent adjacency in Blood Culture Tests Market